Victorian Breast and Oncology Care
Welcome,         Profile    Billing    Logout  
 5 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cescon, David
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Recruiting
3
1295
Canada, US
Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
05/33
05/33
NCT04176848: CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer

Active, not recruiting
2
15
Canada
CFI-400945, Durvalumab, IMFINZI
Canadian Cancer Trials Group, AstraZeneca, University Health Network, Toronto
Breast Cancer
09/22
12/24
NCT03624543: CFI-400945 in Patients With Advanced/Metastatic Breast Cancer

Active, not recruiting
2
51
Canada
CFI-400945
Canadian Cancer Trials Group, Stand Up To Cancer Canada-Canadian Cancer Society Breast Cancer Dream Team
Breast Cancer
12/24
12/25
NCT05601440: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting
2
484
Canada
RP-6306, Lunresertib, Gemcitabine, Observation, Niraparib, Fulvestrant, RP-3500, Camonsertib
Canadian Cancer Trials Group
Breast Cancer
12/27
06/28
GENIUS, NCT03740503: Genomic Investigation of Unusual Responders

Recruiting
N/A
100
Canada
University Health Network, Toronto
Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Gynecological Cancer, Upper Aerodigestive Tract Cancer, Pancreatobiliary Gastrointestinal Cancer, Melanoma (Skin), Rare Cancer, Carcinoma of Unknown Primary
11/25
11/25
REFLECT, NCT02732860: Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host

Recruiting
N/A
120
Canada
Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
University Health Network, Toronto
Colorectal Neoplasms, Colorectal Cancer, Breast Cancer, Breast Neoplasms, Ovarian Cancer, Ovarian Neoplasm
01/26
01/26
Chipman, Mitchell
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26
ACTRN12606000305527: A clinical trial of neoadjuvant taxane chemotherapy for women with locally advanced breast cancer

Active, not recruiting
2
40
 
The Cancer Council Victoria, The Cancer Council Victoria
Locally advanced breast cancer
 
 
Balcewicz, Margaret
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Active, not recruiting
3
250
Canada, RoW
Ipatasertib, Fulvestrant, Placebo
Canadian Cancer Trials Group, Hoffmann-La Roche
Breast Cancer
12/24
12/26

Download Options